Bernie Sanders targets ‘outrageously high price’ of Ozempic

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Here in Chicago, residents are reeling over the removal of the famed rat hole, a rat-shaped indentation on a piece of sidewalk that drew crowds, fans, and even a proposal and a marriage.

The need-to-know this morning

• AstraZeneca reported first-quarter sales and profits that topped analyst estimates, buoyed by its blockbuster cancer drugs.
• It’s a busy day for pharma earnings: Merck, Sanofi, Daiichi Sankyo, Astellas, and Bristol Myers Squibb.
• Regeneron Pharmaceuticals and Mammoth Biosciences are partnering to develop new CRISPR-based gene therapies.

A hospital takes a gene therapy’s approval into its own hands

What happens if, as an academic, you develop a promising gene therapy, but no company is willing to take it to market? Well, one option is — you do it yourself.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In